Dermata Therapeutics (DRMA) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermata Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRMA shares.
View DRMA analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Dermata Therapeutics' shares. Their DRMA share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 273.8% from the stock's current price.
View analysts price targets for DRMA or view top-rated stocks among Wall Street analysts.

Dermata Therapeutics' stock was trading at $6.5440 at the beginning of 2023. Since then, DRMA stock has decreased by 83.6% and is now trading at $1.07.
View the best growth stocks for 2023 here.

Dermata Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 600 shares, a decrease of 95.8% from the August 15th total of 14,400 shares. Based on an average daily trading volume, of 175,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company's shares are sold short.
View Dermata Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our DRMA earnings forecast.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) issued its earnings results on Thursday, August, 10th. The company reported ($0.63) earnings per share for the quarter.

Dermata Therapeutics's stock reverse split on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

(DRMA) raised $18 million in an IPO on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

Dermata Therapeutics trades on the NASDAQ under the ticker symbol "DRMA."

Dermata Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.41%), Virtu Financial LLC (1.37%) and Citadel Advisors LLC (0.54%).

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRMA stock can currently be purchased for approximately $1.07.

Dermata Therapeutics (NASDAQ:DRMA) has a market capitalization of $3.41 million. The company earns $-9,610,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis.

The official website for the company is www.dermatarx.com. The company can be reached via phone at 858-800-2543 or via email at sproehl@dermatarx.com.